VitaSpring Biomedical Co. Ltd.
VSBC
$1.00
$0.000.00%
OTC PK
| 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | 10/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 179.13% | 1,305.72% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 179.13% | 1,305.72% | -- |
| Cost of Revenue | -- | -- | 213.61% | 1,389.71% | -- |
| Gross Profit | -- | -- | 136.86% | 1,203.92% | -- |
| SG&A Expenses | 16.13% | 93.09% | 269.06% | -40.95% | 411.36% |
| Depreciation & Amortization | -- | 375.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.81% | -84.69% | 224.05% | 287.52% | 968.04% |
| Operating Income | -33.02% | -169.22% | 90.83% | 444.15% | -335.13% |
| Income Before Tax | -33.53% | -169.55% | 95.99% | 443.74% | -332.39% |
| Income Tax Expenses | -- | -- | 233.21% | -- | -- |
| Earnings from Continuing Operations | -0.36% | -157.43% | 17.39% | 372.32% | -332.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.36% | -157.43% | 17.39% | 372.32% | -332.39% |
| EBIT | -33.02% | -169.22% | 90.83% | 444.15% | -335.13% |
| EBITDA | -34.03% | -167.58% | -- | 445.42% | -324.44% |
| EPS Basic | 0.00% | -158.33% | 18.18% | 428.57% | -16.67% |
| Normalized Basic EPS | -50.00% | -162.50% | 120.00% | 550.00% | 0.00% |
| EPS Diluted | 0.00% | -158.33% | 18.18% | 428.57% | -16.67% |
| Normalized Diluted EPS | -50.00% | -162.50% | 120.00% | 550.00% | 0.00% |
| Average Basic Shares Outstanding | 0.52% | 0.52% | 0.54% | -18.79% | 276.92% |
| Average Diluted Shares Outstanding | 0.52% | 0.52% | 0.54% | -18.79% | 276.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |